# Cholecystokinin A Receptor Knockdown Diminishes Colon Cancer Cell Invasive Potential via Modulation of Integrin/FAK, EMT, and uPA/uPAR/MMP2 Axis

**Authors:** Chun-Shiang Lin, Ta-Wen Hsu, Hsiang-Lin Lee, Shao-Hsuan Kao

PMC · DOI: 10.32604/or.2026.074231 · Oncology Research · 2026-03-23

## TL;DR

This study shows that reducing CCKAR in colon cancer cells decreases their ability to invade, possibly through changes in cell signaling and structure.

## Contribution

The study reveals a novel mechanism by which CCKAR influences colon cancer invasiveness through integrin/FAK, EMT, and uPA/uPAR/MMP2 pathways.

## Key findings

- CCKAR knockdown reduced cell motility and invasiveness in DLD-1 and LoVo colon cancer cells.
- CCKAR knockdown modulated EMT markers and reduced uPA/uPAR and MMP2 activity.
- Phosphorylation of FAK, Src, and paxillin was diminished following CCKAR knockdown.

## Abstract

Cholecystokinin A receptor (CCKAR) has been linked to poor prognosis in colon cancer patients, but the role of CCKAR in colon cancer cell invasiveness and the underlying mechanisms remain elusive. This study aimed to explore the effect of CCKAR on the invasive potential of colon cancer cells.

Different human colon cancer cell lines were used. Gene expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR (qPCR), while protein expression and phosphorylation were assessed by Western blotting. Cell motility and invasiveness were examined through wound healing and invasion assays, respectively.

Our results showed that CCKAR expression levels varied across colon cancer cell lines, with DLD-1 and LoVo cells showing high expression. Knockdown of CCKAR significantly impaired the cell motility and invasiveness of DLD-1 and LoVo cells, downregulated integrin β3 expression, and diminished the phosphorylation levels of focal adhesion kinase (FAK), Src, and paxillin. In addition, CCKAR knockdown modulated epithelial-mesenchymal transition (EMT) markers ZO-1, E-cadherin, and vimentin and reduced urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), Rho GTPase cell division control protein 42 (CDC42) and RhoA, and matrix metalloproteinase-2 (MMP-2).

These findings indicate that CCKAR knockdown impairs the invasiveness of colon cancer cells, which may be attributed to modulating integrin/FAK/Rho GTPases, EMT markers, and the uPA/uPAR axis. It suggests that targeting CCKAR may represent a potential therapeutic strategy for colon cancer treatment.

## Linked entities

- **Genes:** CCKAR (cholecystokinin A receptor) [NCBI Gene 886], PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], LOC575064 (leupaxin) [NCBI Gene 575064], TJP1 (tight junction protein 1) [NCBI Gene 7082], shg (shotgun) [NCBI Gene 37386], PRELID1 (PRELI domain containing 1) [NCBI Gene 737446], PLAU (plasminogen activator, urokinase) [NCBI Gene 5328], PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329], CDC42 (cell division cycle 42) [NCBI Gene 998], RHOA (ras homolog family member A) [NCBI Gene 387], MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313]
- **Diseases:** colon cancer (MONDO:0002032)

## Full-text entities

- **Genes:** SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, ITGB3 (integrin subunit beta 3) [NCBI Gene 3690] {aka BDPLT16, BDPLT2, BDPLT24, CD61, FMAIT1, GP3A}, VIM (vimentin) [NCBI Gene 7431], CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, CCKAR (cholecystokinin A receptor) [NCBI Gene 886] {aka CCK-1R, CCK-A, CCK1-R, CCK1R, CCKRA}, PXN (paxillin) [NCBI Gene 5829], PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329] {aka CD87, U-PAR, UPAR, URKR}
- **Diseases:** Colon Cancer (MESH:D015179)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13040287/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13040287/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC13040287/full.md

---
Source: https://tomesphere.com/paper/PMC13040287